BioPorto Logo

BioPorto

An in vitro diagnostics company specializing in biomarkers for early kidney injury detection.

BIOPOR | CO

Overview

Corporate Details

ISIN(s):
DK0011048619
LEI:
5299004SWFL5JAN4W830
Country:
Denmark
Address:
Tuborg Havnevej 15, st., 2900 Hellerup

Description

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-10 16:19 Danish 8.5 KB
2025-06-10 16:19 English 7.9 KB
2025-06-10 16:19 English 90.8 KB
2025-06-10 16:19 Danish 119.0 KB
2025-04-25 13:55 English 28.4 KB
2025-04-25 13:55 Danish 155.6 KB
2025-04-25 13:55 English 133.6 KB
2025-04-25 13:55 Danish 28.7 KB
2025-04-25 13:45 English 84.5 KB
2025-04-25 13:45 Danish 114.6 KB
2025-04-25 13:45 English 5.8 KB
2025-04-25 13:45 Danish 5.7 KB
2025-04-14 16:55 English 12.7 KB
2025-04-14 16:55 Danish 12.5 KB
2025-04-14 16:55 English 531.1 KB

Automate Your Workflow. Get a real-time feed of all BioPorto filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioPorto

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioPorto via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.